We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insights Into Ashland (ASH) Q1: Wall Street Projections for Key Metrics
Read MoreHide Full Article
In its upcoming report, Ashland (ASH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.21 per share, reflecting a decline of 78.4% compared to the same period last year. Revenues are forecasted to be $478.44 million, representing a year-over-year decrease of 8.9%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Ashland metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Revenue- Intermediates' will likely reach $36.08 million. The estimate indicates a year-over-year change of -33.2%.
The collective assessment of analysts points to an estimated 'Revenue- Life Sciences' of $203.33 million. The estimate indicates a change of -1.8% from the prior-year quarter.
It is projected by analysts that the 'Revenue- Personal Care' will reach $130.94 million. The estimate indicates a year-over-year change of -5.1%.
The consensus estimate for 'Revenue- Specialty Additives' stands at $127.24 million. The estimate indicates a change of -11% from the prior-year quarter.
Analysts expect 'Adjusted EBITDA- Life Science' to come in at $47.97 million. Compared to the present estimate, the company reported $52 million in the same quarter last year.
The consensus among analysts is that 'Adjusted EBITDA- Personal Care' will reach $25.67 million. The estimate is in contrast to the year-ago figure of $32 million.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Specialty Additives' should arrive at $6.93 million. Compared to the present estimate, the company reported $23 million in the same quarter last year.
Over the past month, Ashland shares have recorded returns of -4.5% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), ASH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Insights Into Ashland (ASH) Q1: Wall Street Projections for Key Metrics
In its upcoming report, Ashland (ASH - Free Report) is predicted by Wall Street analysts to post quarterly earnings of $0.21 per share, reflecting a decline of 78.4% compared to the same period last year. Revenues are forecasted to be $478.44 million, representing a year-over-year decrease of 8.9%.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings announcement, it is crucial to consider revisions to earnings estimates. This serves as a significant indicator for predicting potential investor actions regarding the stock. Empirical research has consistently demonstrated a robust correlation between trends in earnings estimate revision and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
That said, let's delve into the average estimates of some Ashland metrics that Wall Street analysts commonly model and monitor.
The combined assessment of analysts suggests that 'Revenue- Intermediates' will likely reach $36.08 million. The estimate indicates a year-over-year change of -33.2%.
The collective assessment of analysts points to an estimated 'Revenue- Life Sciences' of $203.33 million. The estimate indicates a change of -1.8% from the prior-year quarter.
It is projected by analysts that the 'Revenue- Personal Care' will reach $130.94 million. The estimate indicates a year-over-year change of -5.1%.
The consensus estimate for 'Revenue- Specialty Additives' stands at $127.24 million. The estimate indicates a change of -11% from the prior-year quarter.
Analysts expect 'Adjusted EBITDA- Life Science' to come in at $47.97 million. Compared to the present estimate, the company reported $52 million in the same quarter last year.
The consensus among analysts is that 'Adjusted EBITDA- Personal Care' will reach $25.67 million. The estimate is in contrast to the year-ago figure of $32 million.
Based on the collective assessment of analysts, 'Adjusted EBITDA- Specialty Additives' should arrive at $6.93 million. Compared to the present estimate, the company reported $23 million in the same quarter last year.
View all Key Company Metrics for Ashland here>>>
Over the past month, Ashland shares have recorded returns of -4.5% versus the Zacks S&P 500 composite's +2.5% change. Based on its Zacks Rank #3 (Hold), ASH will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>